抗菌药物联合方案的评估与建模
该综述指出,当前基于参考模型的联合药效量化方法存在局限,无法考虑不同敏感性亚群、明确交互机制及自发突变;文章介绍了基于机制数学模型的方法,利用棋盘微量稀释法和中空纤维感染模型数据评估联合方案,为设计可转化至临床的高活性联合方案提供平台。
要点
- 现有联合药效参考模型未考虑不同敏感性亚群、交互机制及自发突变。
- 基于机制的数学模型可描述药物效应时程并纳入不同药物机制与病原敏感性。
- 棋盘法和中空纤维感染模型数据可用于评估和优化联合方案。
核心结论
- 基于机制的数学建模为描述联合用药效应时程提供了优秀平台,可整合组学数据以设计有效联合疗法。
研究设计与样本
- 综述,检索PubMed、已识别研究和综述的参考文献,并在证据不足时结合个人经验。
主要发现
- 现有参考模型未考虑不同敏感性亚群、未量化交互机制、未纳入自发突变。
- 利用体外棋盘协同面板数据开发了较少依赖模型的联合方案评估方法。
- 利用中空纤维感染模型中利奈唑胺和利福平单药及联合治疗结核分枝杆菌的数据,建立了基于机制的药代动力学/药效学模型。
临床怎么用
- 临床可借助机制数学模型优化联合方案设计,以应对耐药威胁。
局限性
- 证据不足时结合了个人经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increasing global prevalence of multidrug-resistant bacteria is forcing clinicians to prescribe combination antibiotic regimens to treat serious infections. Currently, the joint activity of a combination is quantified by comparing the observed and expected effects using a reference model. These reference models make different assumptions and interpretations of synergy. They fail to: (i) account for multiple bacterial subpopulations with differing susceptibilities; (ii) quantify or interpret the explicit interaction (synergy/antagonism) mechanisms; and (iii) accommodate spontaneous mutations. AIMS: To develop better study designs, mathematical models, metrics and pharmacodynamic analyses to assist with the identification of highly active combinations that are translatable to the clinical context to address the mounting antibiotic resistance threat. SOURCES: PubMed, references of identified studies and reviews, and personal experience when evidence was lacking. CONTENT: We reviewed metrics and approaches for quantifying the joint activity of the combination. The first example is using experimental data from an in vitro checkerboard synergy panel to develop and illustrate a less model-dependent method for assessing combination regimens. In the second example a pharmacokinetic/pharmacodynamic model was developed using mechanism-based mathematical modelling and monotherapy and combination therapy data obtained from an in vitro hollow fibre infection model evaluating linezolid and rifampin regimens against Mycobacterium tuberculosis. IMPLICATIONS: Mechanism-based mathematical approach provides an excellent platform for describing the time course of effect while taking into account the mechanisms of different antibiotics and differing pathogen susceptibilities. This approach allows for the future integration of 'omics' data describing host-pathogen interactions, that will provide a systems-level understanding of the underlying infectious process, and enable the design of effective combination therapies.
引用
- Rao GG, Li J, Garonzik SM, et al. Assessment and modelling of antibacterial combination regimens. Clin Microbiol Infect. 2017. PMID: 29269090. doi:10.1016/j.cmi.2017.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。